Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones

Pediatric Pulmonology

Volumn 48, Issue 3, 2013, Pages 211-220

  Stockmann, Chris ^a   Sherwin, Catherine M T ^a   Zobell, Jeffery T ^b,c   Young, David C ^d,e   Waters, C Dustin ^f   Spigarelli, Michael G ^a   Ampofo, Krow ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^c Intermountain Cystic Fibrosis Pediatric Center   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Intermountain Cystic Fibrosis Adult Center   (United States)

^f McKay Dee Hospital Center   (United States)

Author keywords

ciprofloxacin; levofloxacin; pharmacodynamics; pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

AZLOCILLIN; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE; TOBRAMYCIN;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHROPATHY; ARTICLE; CHILL; CONJUNCTIVITIS; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ECZEMA; FATIGUE; FLATULENCE; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INSOMNIA; LIMB PAIN; LUNG FUNCTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRURITUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TASTE DISORDER; TENDON DISEASE; THROMBOPHLEBITIS; TREMOR; URTICARIA; VAGINITIS; VOMITING;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84874106381     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22667     Document Type: Article

References (47)

1. Ramsey BW,. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 335: 179-188.
2. Pamukcu A, Bush A, Buchdahl R,. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995; 19: 10-15.
3. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, and the Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
4. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA,. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011.
5. Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
6. Wolfson JS, Hooper DC,. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378-424.
7. Drlica K, Zhao X,. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-392.
8. Andersson MI, MacGowan AP,. Development of the quinolones. J Antimicrob Chemother 2003; 51: 1-11.
9. CIPRO® Approved Package Labeling. Bayer HealthCare Pharmaceuticals, 2011.
10. Fish DN, Choi MK, Jung R,. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002; 50: 1045-1049.
11. Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, Smith AL,. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987; 31: 915-919.
12. Drug Information Handbook, Lexi-Comp, Inc.
13. Pediatric Dosage Handbook, Lexi-Comp, Inc.
14. Croom KF, Goa KL,. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-2802.
15. Levaquin® Approved Package labeling, Ortho-McNeil-Janssen Pharmaceuticals, Inc.
16. Reed MD, Stern RC, Myers CM, Yamashita TS, Blumer JL,. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol 1988; 28: 691-699.
17. Smith MJ, White LO, Bowyer H, Willis J, Hodson ME, Batten JC,. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother 1986; 30: 614-616.
18. Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg AS, Hjelte L, Strandvik B,. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1992; 36: 2512-2517.
19. Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, Schaad UB,. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40: 29-34.
20. LeBel M, Bergeron MG, Vallee F, Fiset C, Chasse G, Bigonesse P, Rivard G,. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1986; 30: 260-266.
21. Stutman HR, Shalit I, Marks MI, Greenwood R, Chartrand SA, Hilman BC,. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. Am J Med 1987; 82: 142-145.
22. Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA,. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J 1997; 16: 112-117; discussion 123-116.
23. Szalek E, Kaminska A, Gozdzik-Spychalska J, Grzeskowiak E, Batura-Gabryel H,. The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis. Acta poloniae pharmaceutica 2011; 68: 777-783.
24. Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, Jacqz-Aigrain E,. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother 2003; 47: 3170-3178.
25. Rajagopalan P, Gastonguay MR,. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol 2003; 43: 698-710.
26. Golper TA, Hartstein AI, Morthland VH, Christensen JM,. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1987; 31: 1787-1790.
27. Hoffken G, Lode H, Wiley R, Glatzel TD, Sievers T, Olschewski K, Borner K, Koeppe T,. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effects of food and antacid intake. Rev Infect Dis 1988; 10: S138-S139.
28. Polk RE, Healy DP, Sahai J, Drwal L, Racht E,. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989; 33: 1841-1844.
29. Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar JR, Jullien V,. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. Pharmacotherapy 2010; 30: 1252-1258.
30. Schentag JJ, Nix DE, Adelman MH,. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991; 25: 1050-1057.
31. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA,. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 3468-3473.
32. Lee CK, Boyle MP, Diener-West M, Brass-Ernst L, Noschese M, Zeitlin PL,. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest 2007; 131: 796-802.
33. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT,. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-2260.
34. Pai MP, Allen SE, Amsden GW,. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. J Cyst Fibros 2006; 5: 153-157.
35. Pickerill KE, Paladino JA, Schentag JJ,. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 2000; 20: 417-428.
36. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC,. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987; 1: 235-237.
37. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB,. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997; 16: 572-578.
38. Marks MI,. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr 1981; 98: 173-179.
39. Kato M, Takada S, Ogawara S, Takayama S,. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother 1995; 39: 1979-1983.
40. Vormann J, Forster C, Zippel U, Lozo E, Gunther T, Merker H, Stahlmann R,. Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcif Tissue Int 1997; 61: 230-238.
41. Spencker FB, Staber L, Lietz T, Schille R, Rodloff AC,. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin Microbiol Infect 2003; 9: 370-379.
42. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R,. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2): S146-155.
43. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A,. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532-537.
44. Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, Painter BG, Thurberg BE, Haverstock DC, Perroncel RY, Echols RM,. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/ tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997; 16: 97-105; discussion 123-106.
45. LeBel M,. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal. Eur J Clin Microbiol Infect Dis 1991; 10: 316-324.
46. Valerius NH, Koch C, Hoiby N,. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 1991; 338: 725-726.
47. Golini G, Favari F, Marchetti F, Fontana R,. Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2004; 23: 798-800.